Sanofi India - Reassuring Commitment To India: ICICI Securities

ICICI Securities Report

Sanofi India Ltd.’s CY23 annual report reiterates its commitment towards Indian market and the developments across its four pillars of growth, viz., diabetes, consumer healthcare, innovation and go-to-market.

Price cut (20% value decline in CY23) is helping its Lantus brand gain volume market share while the company is on course to launch Soliqua, an fixed ratio combination of basal insulin and GLP 1 (Glucagon-Like Peptide) analog in CY24.

Sanofi India is on track to demerge the consumer arm in H2 CY24. Further, it has entered into partnerships with domestic companies like Cipla Ltd. and Emcure to enhance distribution of its CNS and cardiac brands and rationalise own field force.

The stock trades at attractive 27 times FY26E earnings. Upgrade to Add with an unchanged target price of Rs 9,170.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.